Radiology 2020 02 26;294(2):377-385. Epub 2019 Nov 26.
From the Departments of Radiology (O.M., N.H., N.L., A.Z.M., C.W.F., X.L., J.A.M., H.J., A.G., J.A.S., S.W.A., L.E.G.), Neurology (A.C.M., L.E.G.), Pathology and Laboratory Medicine (V.E.A., B.R.H., A.C.M., L.E.G.), Behavioral Neuroscience (S.E.C.), and Anatomy and Neurobiology (K.J.B.), Boston University School of Medicine, 670 Albany St, Boston, MA 02118; Boston University Alzheimer's Disease Center, Boston, Mass (O.M., N.H., P.T.K., L.E.E., S.E.C., J.A.M., V.E.A., B.R.H., A.C.M., L.E.G.); VA Boston Healthcare System, Jamaica Plain, Mass (A.M.H., V.E.A., B.R.H., A.C.M.); Stroke Branch, National Institute of Neurologic Diseases and Stroke, National Institutes of Health, Bethesda, Md (A.D.G., L.L.L.); Center for Neuroscience and Regenerative Medicine, Uniformed Services University, Bethesda, Md (A.D.G., L.L.L.); and Center for Biometals and Metallomics (O.M., N.L., J.A.M., L.E.G.), College of Engineering (E.S.F., A.C.M., S.W.A., L.E.G.), and Photonics Center (O.M., J.A.M., S.W.A., L.E.G.), Boston University, Boston, Mass.
Background Gadolinium retention after repeated gadolinium-based contrast agent (GBCA) exposure has been reported in subcortical gray matter. However, gadolinium retention in the cerebral cortex has not been systematically investigated. Purpose To determine whether and where gadolinium is retained in rat and human cerebral cortex. Materials and Methods The cerebral cortex in Sprague-Dawley rats treated with gadopentetate dimeglumine (three doses over 4 weeks; cumulative gadolinium dose, 7.2 mmol per kilogram of body weight; = 6) or saline ( = 6) was examined with antemortem MRI. Two human donors with repeated GBCA exposure (three and 15 doses; 1 and 5 months after exposure), including gadopentetate dimeglumine, and two GBCA-naive donors were also evaluated. Elemental brain maps (gadolinium, phosphorus, zinc, copper, iron) for rat and human brains were constructed by using laser ablation inductively coupled plasma mass spectrometry. Results Gadopentetate dimeglumine-treated rats showed region-, subregion-, and layer-specific gadolinium retention in the neocortex (anterior cingulate cortex: mean gadolinium concentration, 0.28 µg ∙ g ± 0.04 [standard error of the mean]) that was comparable ( > .05) to retention in the allocortex (mean gadolinium concentration, 0.33 µg ∙ g ± 0.04 in piriform cortex, 0.24 µg ∙ g ± 0.04 in dentate gyrus, 0.17 µg ∙ g ± 0.04 in hippocampus) and subcortical structures (0.47 µg ∙ g ± 0.10 in facial nucleus, 0.39 µg ∙ g ± 0.10 in choroid plexus, 0.29 µg ∙ g ± 0.05 in caudate-putamen, 0.26 µg ∙ g ± 0.05 in reticular nucleus of the thalamus, 0.24 µg ∙ g ± 0.04 in vestibular nucleus) and significantly greater than that in the cerebellum (0.17 µg ∙ g ± 0.03, = .01) and white matter tracts (anterior commissure: 0.05 µg ∙ g ± 0.01, = .002; corpus callosum: 0.05 µg ∙ g ± 0.02, = .001; cranial nerve: 0.02 µg ∙ g ± 0.01, = .004). Retained gadolinium colocalized with parenchymal iron. T1-weighted MRI signal intensification was not observed. Gadolinium retention was detected in the cerebral cortex, pia mater, and pia-ensheathed leptomeningeal vessels in two GBCA-exposed human brains but not in two GBCA-naive human brains. Conclusion Repeated gadopentetate dimeglumine exposure is associated with gadolinium retention in specific regions, subregions, and layers of cerebral cortex that are critical for higher cognition, affect, and behavior regulation, sensorimotor coordination, and executive function. © RSNA, 2019 See also the editorial by Kanal in this issue.